Pharmacological Institute, College of Medicine, National Taiwan University, Taipei, Taiwan.
Cancer Lett. 2013 Aug 19;336(2):370-8. doi: 10.1016/j.canlet.2013.03.028. Epub 2013 Apr 6.
Here, we report that TW01001, a novel piperazinedione compound, could be a new mitotic inhibitor for the treatment of non-small cell lung cancer by the following observations in A549 cells: (1) induction of cells to accumulate at G2/M phase, which ultimately led to cell apoptotic death, (2) accumulation of p53 and inhibition of survival signalings, and (3) induction of p53-independent autophagy. Taken together, our data suggested that TW01001 induces autophagy-p53-signaling pathway to cause mitotic arrest and cell growth inhibition in A549 cells and provides the framework for further development as a novel therapeutic agent for lung cancer treatment.
在这里,我们报道了 TW01001,一种新型哌嗪二酮化合物,通过在 A549 细胞中的以下观察结果,可能成为治疗非小细胞肺癌的新型有丝分裂抑制剂:(1)诱导细胞积累在 G2/M 期,最终导致细胞凋亡死亡,(2)p53 的积累和生存信号的抑制,以及(3)p53 非依赖性自噬的诱导。总之,我们的数据表明 TW01001 诱导自噬-p53-信号通路导致 A549 细胞中的有丝分裂阻滞和细胞生长抑制,并为进一步开发作为肺癌治疗的新型治疗剂提供了框架。